Kirkeby Cell Therapy APS: Financial statements 2022
CVR: 38650165
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Kirkeby Cell Therapy APS (CVR 38650165) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 107,768 and a net result of DKK 127,623 compared with DKK 281,249 the year before. That is a decrease of 56.3% compared with the year before. Equity in the 2022 report amounted to DKK 1,590,245. The solvency ratio was 94.5%.
- Gross Profit
- DKK 107,768
- Profit/Loss
- DKK 127,623
- Equity
- DKK 1,590,245
- Total Assets
- DKK 1,682,627
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 108K | 128K | 1.6M | - |
| 2021 | - | 247K | 281K | 1.6M | - |
| 2020 | - | 180K | 184K | 1.3M | - |
| 2019 | - | 189K | 256K | 1.1M | - |
| 2018 | - | 120K | 71K | 937K | - |
Official annual report
Keep an eye on Kirkeby Cell Therapy APS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Kirkeby Cell Therapy APS has published its annual report for 2021. Gross profit came to DKK 246,593, and the net result was DKK 281,249.
About Kirkeby Cell Therapy APS
Kirkeby Cell Therapy APS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2017. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Kirkeby Cell Therapy IVS and Kirkeby Cell Therapey IVS. The management consists of Agnete Kirkeby. The company is owned by Agnete Kirkeby. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 25,872 and a net result of DKK -19,504 compared with DKK 111,159 the year before. Equity in the 2025 report amounted to DKK 1,541,351.